SCHEMBL46465

SCHEMBL46465

CCOC(=O)CN1C(=O)S/C(=C\c2ccc(N3CCCC3)o2)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 6/20 1.00
ITGAM P11215 6/20 1.00
MEN1 O00255 8/20 0.98
KMT2A Q03164 8/20 0.98
MAPT P10636 6/20 0.98
ALDH1A1 P00352 4/20 0.98
CYP1A2 P05177 2/20 0.98
CYP3A4 P08684 2/20 0.98
CYP2C19 P33261 2/20 0.98
KDM4E B2RXH2 5/20 0.80
HTT P42858 3/20 0.80
PKM P14618 3/20 0.80
RAB9A P51151 3/20 0.80
NPSR1 Q6W5P4 2/20 0.80
USP2 O75604 2/20 0.80
LMNA P02545 1/20 0.80
GAA P10253 1/20 0.80
CYP2C9 P11712 1/20 0.80
TDP1 Q9NUW8 3/20 0.59
MAPK1 P28482 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL46460 0.92 ITGB2 (0.85) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL46467 0.84 MEN1 (1.00) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL46558 0.79 ITGB2 (1.00) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL684265 0.77 ITGB2 (1.00) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL46469 0.77 ITGB2 (0.74) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL46217 0.76 ITGB2 (0.80) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL46561 0.76 ITGB2 (1.00) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL683059 0.76 ITGB2 (1.00) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL5147456 0.76 SLC1A3 (0.88) ITGB2ITGAMMEN1KMT2AMAPT
SCHEMBL46577 0.76 SLC1A3 (0.88) ITGB2ITGAMMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3243821-B1 PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 GB006 INC (US) 2020-02-26 EP disclosed
EP-2838614-B1 COMPOSITIONS FOR REGULATING INTEGRINS GB006 INC (US) 2019-09-11 EP disclosed
US-10239871-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2019-03-26 US disclosed
US-20160151336-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2016-06-02 US disclosed
US-20160151336-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2016-06-02 US disclosed
US-9328105-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2016-05-03 US disclosed
US-9328105-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2016-05-03 US disclosed
US-9023876-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2015-05-05 US disclosed
US-9023876-B2 Compounds and methods for regulating integrins ADHAERE PHARMACEUTICALS, INC. (US) 2015-05-05 US disclosed
US-20150105435-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2015-04-16 US disclosed
US-20150105435-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ATEGRIN, INC. 2015-04-16 US disclosed
US-20120010255-A1 Compounds and Methods for Regulating Integrins ATEGRIN, INC. 2012-01-12 US disclosed
US-20120010255-A1 Compounds and Methods for Regulating Integrins ATEGRIN, INC. 2012-01-12 US disclosed
WO-2012005800-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 ADHAERE PHARAMACEUTICALS, INC. (US) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239871-B2 Compounds and methods for regulating integrins ITGA2, ITGB2, ITGA2B ITGB2 2/4885ITGAM 9/4885MEN1 2635/4885
US-20120010255-A1 Compounds and Methods for Regulating Integrins ITGB8, ITGB3, ITGAM ITGB2 5/4885ITGAM 3/4885MEN1 1586/4885
US-20150105435-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ITGA2, ITGB2, ITGA2B ITGB2 2/4885ITGAM 9/4885MEN1 2635/4885
US-20160151336-A1 COMPOUNDS AND METHODS FOR REGULATING INTEGRINS ITGA2, ITGB2, ITGA2B ITGB2 2/4885ITGAM 9/4885MEN1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.